Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGNDZ) Long-Term Debt Issuances (2018 - 2022)

Ligand Pharmaceuticals (LGNDZ) has disclosed Long-Term Debt Issuances for 6 consecutive years, with $202000.0 as the latest value for Q3 2022.

  • Quarterly Long-Term Debt Issuances fell 90.3% to $202000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $202000.0 through Dec 2024, changed 0.0% year-over-year, with the annual reading at $460.0 million for FY2025, N/A changed from the prior year.
  • Long-Term Debt Issuances hit $202000.0 in Q3 2022 for Ligand Pharmaceuticals, down from $2.1 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $16.9 million in Q1 2021 to a low of -$310.4 million in Q4 2018.
  • Historically, Long-Term Debt Issuances has averaged -$55.8 million across 4 years, with a median of $2.1 million in 2021.
  • Biggest YoY gain for Long-Term Debt Issuances was 90.3% in 2022; the steepest drop was 90.3% in 2022.
  • Year by year, Long-Term Debt Issuances stood at -$310.4 million in 2018, then surged by 103.99% to $12.4 million in 2019, then plummeted by 83.2% to $2.1 million in 2021, then crashed by 90.3% to $202000.0 in 2022.
  • Business Quant data shows Long-Term Debt Issuances for LGNDZ at $202000.0 in Q3 2022, $2.1 million in Q3 2021, and $16.9 million in Q1 2021.